Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis

Journal of Pathology

Volumn 230, Issue 4, 2013, Pages 377-387

  Chung, Yih Lin ^a   Wu, Mei Ling ^a  

^a KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

Author keywords

DNA damage response and repair; hepatitis B virus; hepatitis B virus surface antigen; hepatocellular carcinoma; promyelocytic leukaemia protein

Indexed keywords

ANDROGEN; HEPATITIS B SURFACE ANTIGEN; PROMYELOCYTIC LEUKEMIA PROTEIN; VIRUS DNA;

ANDROGEN METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; FATTY LIVER; GENE INACTIVATION; GENOMIC INSTABILITY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; LIVER; LIVER ADENOMA; LIVER BIOPSY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINATION REPAIR; SPLEEN CELL; VIRUS CARCINOGENESIS;

DNA DAMAGE RESPONSE AND REPAIR; HEPATITIS B VIRUS; HEPATITIS B VIRUS SURFACE ANTIGEN; HEPATOCELLULAR CARCINOMA; PROMYELOCYTIC LEUKAEMIA PROTEIN;

ADIPOSITY; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; BIOPSY; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, VIRAL; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA REPAIR; DOXORUBICIN; FATTY LIVER; FEMALE; GENOMIC INSTABILITY; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NUCLEAR PROTEINS; SEX FACTORS; TIME FACTORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 84880082500     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4195     Document Type: Article

References (29)

1. Lunardi A, Gaboli M, Giorgio M, et al,. A role for PML in innate immunity. Genes Cancer 2011; 2: 10-19.
2. Zheng P, Guo Y, Niu Q, et al,. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 1998; 396: 373-376.
3. Giorgi C, Ito K, Lin HK, et al,. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 2010; 330: 1247-1251.
4. Rivera OJ, Song CS, Centonze VE, et al,. Role of the promyelocytic leukemia body in the dynamic interaction between the androgen receptor and steroid receptor coactivator-1 in living cells. Mol Endocrinol 2003; 17: 128-140.
5. Boichuk S, Hu L, Makielski K, et al,. Functional connection between Rad51 and PML in homology-directed repair. PLoS One 2011; 6: e25814.
6. Dellaire G, Ching RW, Ahmed K, et al,. Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol 2006; 175: 55-66.
7. Zhong S, Hu P, Ye TZ, et al,. A role for PML and the nuclear body in genomic stability. Oncogene 1999; 18: 7941-7947.
8. Van Damme E, Van Ostade X,. Crosstalk between viruses and PML nuclear bodies: a network-based approach. Front Biosci 2011; 16: 2910-2920.
9. Regad T, Chelbi-Alix MK,. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 2001; 20: 7274-7286.
10. Kim MK, Yang S, Lee KH, et al,. Promyelocytic leukemia inhibits adipogenesis, and loss of promyelocytic leukemia results in fat accumulation in mice. Am J Physiol Endocrinol Metab 2011; 301: E1130-E1142.
11. Carracedo A, Weiss D, Leliaert AK, et al,. A metabolic prosurvival role for PML in breast cancer. J Clin Invest 2012; 122: 3088-3100.
12. Gurrieri C, Capodieci P, Bernardi R, et al,. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004; 96: 269-279.
13. Chung YL, Tsai TY,. Promyelocytic leukemia nuclear bodies link the DNA damage repair pathway with hepatitis B virus replication: implications for hepatitis B virus exacerbation during chemotherapy and radiotherapy. Mol Cancer Res 2009; 7: 1672-1685.
14. Bouchard MJ, Navas-Martin S,. Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett 2011; 305: 123-143.
15. Kremsdorf D, Soussan P, Paterlini-Brechot P, et al,. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006; 25: 3823-3833.
16. Wang ZG, Delva L, Gaboli M, et al,. Role of PML in cell growth and the retinoic acid pathway. Science 1998; 279: 1547-1551.
17. Chisari FV, Klopchin K, Moriyama T, et al,. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145-1156.
18. Yeo W, Zee B, Zhong S, et al,. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311.
19. Na B, Huang Z, Wang Q, et al,. Transgenic expression of entire hepatitis B virus in mice induces hepatocarcinogenesis independent of chronic liver injury. PLoS One 2011; 6: e26240.
20. Zheng Y, Chen WL, Louie SG, et al,. Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice. Hepatology 2007; 45: 16-21.
21. Chung YL,. Defective DNA damage response and repair in liver cells expressing hepatitis B virus surface antigen. FASEB J 2013 Feb 26 doi: 10.1096/fj.12-226639.
22. Yoon GS, Yu E,. Overexpression of promyelocytic leukemia protein and alteration of PML nuclear bodies in early stage of hepatocarcinogenesis. J Korean Med Sci 2001; 16: 433-438.
23. Chan JY, Chin W, Liew CT, et al,. Altered expression of the growth and transformation suppressor PML gene in human hepatocellular carcinomas and in hepatitis tissues. Eur J Cancer 1998; 34: 1015-1022.
24. Hatakeyama S., TRIM proteins and cancer. Nature Rev Cancer 2011; 11: 792-804.
25. Khetchoumian K, Teletin M, Tisserand J, et al,. Loss of Trim24 (Tif1α) gene function confers oncogenic activity to retinoic acid receptor alpha. Nature Genet 2007; 39: 1500-1506.
26. Chambon M, Orsetti B, Berthe ML, et al,. Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer. Am J Pathol 2011; 178: 1461-1469.
27. Herquel B, Ouararhni K, Khetchoumian K, et al,. Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci U S A 2011; 108: 8212-8217.
28. Iglehart JD, Silver DP,. Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 2009; 361: 189-191.
29. Zhao Y, Liu H, Riker AI, et al,. Emerging metabolic targets in cancer therapy. Front Biosci 2011, 16: 1844-1860.